DeCure for Hypothyroidism, congenital, nongoitrous, 2
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for hypothyroidism, congenital, nongoitrous, 2 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypothyroidism, congenital, nongoitrous, 2 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypothyroidism, congenital, nongoitrous, 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Congenital hypothyroidism occurs in roughly 1 in 3000 to 1 in 4000 newborns. It is the most common neonatal endocrine disorder and a preventable cause of mental retardation if caught early by screening. The condition is split into two broad categories: thyroid dysgenesis, where the gland fails to develop normally, and dyshormonogenesis, where a structurally normal gland cannot produce enough hormone. Thyroid dysgenesis accounts for about 85% of primary congenital hypothyroidism cases.
Despite decades of molecular genetics research, the underlying genetic cause remains unknown for the vast majority of patients. In thyroid dysgenesis, known mutations in genes such as PAX8, TTF1 (NKX2-1), and TTF2 (FOXE1) explain only a minority of cases. The defects that have been characterised to date are typically recessive and more common in inbred families, but the sporadic nature of most dysgenesis suggests polygenic or multifactorial origins. Dyshormonogenesis, though less common, is usually a straightforward autosomal recessive condition, but even here the full set of causative genes is not yet complete.
Bioinformatic work on five genes — NIS, PAX8, DUOX2, FOXE1, and NKX2-1 — has identified shared consensus sequence motifs and high protein homology across species, but this in silico evidence does not translate into a clinical test or treatment. The 2025 review confirms that the molecular basis of primary congenital hypothyroidism remains unclear in most cases, and the 2018 review notes that genetic defects are found in only a very low proportion of patients with the commonest form, dysgenesis.
What is still missing is a systematic, large-scale sequencing effort in unselected patient populations, adequate funding for functional validation of candidate genes, and a trial design that can stratify patients by genotype before treatment decisions are made. Without these, the genetic basis of congenital hypothyroidism will remain fragmentary, and no drug repurposing target can be confidently proposed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Endocrinology · 2002 · 127 citations · open access
Perspective: Genetic Defects in the Etiology of Congenital Hypothyroidism
AbstractCongenital hypothyroidism affects about 1:3000 to 1:4000 infants and may be caused by defects in thyroidal ontogeny or hormone synthesis. The impressive advances in molecular genetics led to the characterization of numerous genes that are essential for normal development and hormone production of the hypothalamic-pituitary-thyroid axis. Mutations in many of these genes now provide a molecular explanation for a subset of the sporadic and familial forms of congenital hypothyroidism. Defects in one of the multiple steps required for normal hormone synthesis account for about 10% of cases with congenital hypothyroidism. They are typically recessive and therefore more common in inbred families. In the vast majority of patients, congenital hypothyroidism is sporadic and associated with thyroid dysgenesis, a spectrum of developmental defects, which includes the absence of detectable thyroid tissue, ectopic tissue, and thyroid hypoplasia. The molecular defects known to date only explain a minority of these cases and include mutations in the paired box transcription factor PAX8, and the thyroid transcription factors TTF1 and TTF2. It is likely that a further subset of patients with thyroid dysgenesis have defects in other transacting proteins or elements of the signaling pathways controlling growth and function of thyrocytes. In other instances, thyroid dysgenesis may be a polygenic disease or have a multifactorial basis. Aside from providing fundamental insights into the ontogeny and the pathophysiology of the thyroid, the characterization of the molecular basis of congenital hypothyroidism may have growing importance for genetic testing and counseling in the future.
European Thyroid Journal · 2025 · 16 citations · open access
Genetics of primary congenital hypothyroidism: three decades of discoveries and persisting etiological challenges
AbstractPrimary congenital hypothyroidism (CH) is the most common neonatal endocrine disorder, and may be etiologically subdivided into thyroid dysgenesis, referring to abnormal thyroid development, and dyshormonogenesis, where a defective thyroid hormone biosynthesis pathway results in inadequate hormone production despite a structurally intact gland. Delayed treatment of neonatal hypothyroidism may result in irreversible neurodevelopmental impairment; therefore, where available, CH screening programs facilitate prompt diagnosis. However, the molecular basis for CH remains unclear in most of the cases. This review summarizes current understanding of the genetic etiologies underlying primary CH and associated phenotypes. Classical genetic causes are discussed in the context of their role in normal thyroid physiology. Genes recently reported to play a role in the pathogenesis of CH are discussed, and novel genomic mechanisms in CH are described.
AbstractCongenital hypothyroidism (CH) is one of the most common preventable forms of mental retardation and since the implementation of neonatal screening programs in the mid-1970s, early detection and treatment have proven to be very successful in preventing brain damage. CH may be of thyroidal (= primary) or of hypothalamic-pituitary (= central) origin. Primary CH may be due to abnormal thyroid gland formation (dysgenesis) or defective thyroid hormone syntheses by a structurally normal gland (dyshormonogenesis). While thyroid dysgenesis is the most common form of CH, accounting for approximately 85% of cases, genetic defects are only found in a very low proportion of patients. On the other hand, thyroid dyshormonogenesis is less common, but is usually a genetic condition with autosomal recessive inheritance. In this review we provide an overview of all known monogenetic causes of primary CH, including promising new candidate genes. In addition, alternative genetic mechanisms are discussed.
Journal of the Pakistan Medical Association · 2020 · 1 citations · open access
Insilico study of genes involved in Congenital Hypothyroidism.
AbstractOBJECTIVE: To study the orthologs of the five genes of congenital hypothyroidism NIS, PAX8, DUOX2, FOXE1, NKX2-1 that are involved in the development of the thyroid gland. METHODS: The study was conducted at INMOL Cancer Hospital, Lahore in September 2017 and comprised of finding gene orthologs, phylogenetic tree and domains of NIS, PAX8, DUOX2, FOXE1, NKX2-1 which were studied using different bioinformatics tools, including FASTA, BLAST, ENSEMBL, UniProt, MultiAlin, to find out the important domains involved in the mutations of these genes. RESULTS: Genes showed consensus sequence / motifs involved in congenital hypothyroidism. Phylogenetic results showed that these genes shared some common motifs. Phylogenetic trees revealed sub-clusters with high protein homology. CONCLUSIONS: Genes involved in congenital hypothyroidism were found to have a consensus sequence motifs.
Journal of Clinical Images and Medical Case Reports · 2022 · 1 citations · open access
Cretinism: Case report
AbstractCongenital hypothyroidism is the most common congenital endocrinopathy; it is also the leading cause of preventable mental retardation and has severe socioeconomical consequences. We report the case of a 10 year-old girl admitted for a typical clinical presentation of hypothyroidism with cretinism and dwarfism (height at 78 cm). Treatment was started immediately with levothyroxine. Neonatal screening for this disease should be generalized in our country, not only because it is a cause of avoidable mental retardation, but also because this would be one of the most cost-effective secondary prevention programs.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
